Rein Therapeutics正在为其在研药物Lti-03的二期临床试验RENEW积极招募患者。这项关键性研究的受试者入组工作已全面展开,标志着该候选药物研发进程迈入新的重要阶段。公司方面透露,该试验的中期数据有望在2026年下半年揭晓,届时将为后续开发决策提供关键参考依据。
Rein Therapeutics正在为其在研药物Lti-03的二期临床试验RENEW积极招募患者。这项关键性研究的受试者入组工作已全面展开,标志着该候选药物研发进程迈入新的重要阶段。公司方面透露,该试验的中期数据有望在2026年下半年揭晓,届时将为后续开发决策提供关键参考依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.